Clinical Trial: Anti-oxLDL IgM Antibodies as a Novel Therapy for Metabolic Lipid Diseases
Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Interventional
Official Title: Immunization Against oxLDL in Patients With Lysosomal Lipid Diseases and Associated Metabolic Disorders
Brief Summary: To test whether active pneumococci immunization can alleviate inflammation and improve cholesterol metabolism in lysosomal lipid storage diseases and associated metabolic disorders.
Detailed Summary: Growing evidence describes the central role of oxidized low density lipoproteins (oxLDL) in diseases related to lipid metabolism. Moreover, oxLDL has been shown to be involved in pathological processes such as an inappropriate inflammatory response, disturbance of cholesterol metabolism and dysfunction of the lysosomal apparatus. Relevantly, it has been shown that immunizing mice with Streptococcus pneumoniae results in higher serum titers of anti-oxLDL IgM antibodies due to molecular mimicry.
Sponsor: Universitaire Ziekenhuizen Leuven
Current Primary Outcome: The level of inflammation [ Time Frame: 4 weeks ]
Original Primary Outcome:
- The level of inflammation [ Time Frame: 4 weeks ]
- the level of cholesterol metabolism [ Time Frame: 4 weeks ]
Current Secondary Outcome:
- Levels of lysosomal enzymes [ Time Frame: 4 weeks ]
- the level of cholesterol metabolism [ Time Frame: 4 weeks ]
Original Secondary Outcome: Levels of lysosomal enzymes [ Time Frame: 4 weeks ]
Information By: Universitaire Ziekenhuizen Leuven
Dates:
Date Received: January 20, 2016
Date Started: June 2016
Date Completion: February 2017
Last Updated: March 14, 2016
Last Verified: March 2016
